Weinberger v. Hynson, Westcott & Dunning, Inc.

1973-06-18

Headline: Court upholds FDA’s power to demand rigorous scientific proof of drug effectiveness, allows agency to screen and decide ‘new drug’ status for related products, and requires a hearing on one drug’s submitted evidence.

Holding: The Court held that FDA may use strict scientific standards and a summary screening process to deny hearings when no substantial evidence exists, may decide new-drug status and issue declaratory orders, and required a hearing for Lutrexin.

Real World Impact:

Gives FDA authority to screen and remove drugs lacking scientific proof of effectiveness.
Allows FDA to decide 'new drug' status and issue declaratory orders covering related 'me-too' products.
Requires drug makers to submit adequate, well-controlled investigations to avoid withdrawal.

Topics: drug approval, FDA authority, drug efficacy, administrative hearings, grandfather clause

Summary

Background

A drug manufacturer, Hynson, marketed a product called Lutrexin after earlier approval under the old safety-only rules. Congress amended the drug law in 1962 to require “substantial evidence” of effectiveness. FDA used expert panels to review many marketed drugs, questioned Lutrexin’s efficacy, and moved to withdraw its approval. Hynson sought a court ruling instead of or before an administrative hearing.

Reasoning

The Court examined whether FDA may use strict, science-based regulations and a summary screening process to deny hearings when an applicant offers no substantial evidence. It held that FDA’s rules reflecting the 1962 law are lawful and that the agency may issue declaratory orders and decide whether a product is a “new drug,” covering related “me-too” products. The Court also interpreted “general recognition” to require the same substantial evidence called for by the statute. However, the Court found Hynson’s submission raised a genuine factual issue and therefore ordered a hearing on Lutrexin’s efficacy; the agency’s finding that Lutrexin was exempt under the grandfather clause was rejected.

Real world impact

The ruling confirms FDA’s ability to remove drugs that lack rigorous clinical proof and to act for whole groups of similar products, speeding enforcement. Drug makers must rely on adequate, well-controlled investigations rather than anecdote or physician belief. The decision requires a formal hearing in Hynson’s case, so the final outcome could still change after that process.

Dissents or concurrances

Justice Powell concurred in the result but warned that tougher due-process and statutory questions about the agency’s threshold rules remain and should be decided in future cases.